In short
This article discusses the use of antihistamines for systemic use in clinical trials for advanced urothelial carcinoma (bladder cancer). The trials aim to evaluate the safety, efficacy, and potential benefits of combining antihistamines with other cancer treatments. Understanding these trials can provide valuable insights into new treatment options for patients with this challenging condition.
At a glance
- Study Type
- Phase 1/2 Randomized, Umbrella Study
- Main Objective
- Evaluate safety, tolerability, and efficacy of antihistamines combined with other cancer therapies
- Target Condition
- Advanced Urothelial Carcinoma
- Key Treatments
- Antihistamines, MK-2870, Enfortumab Vedotin, Pembrolizumab
- Primary Endpoints
- Adverse Events, Discontinuation rates, Objective Response Rate
- Secondary Endpoints
- Duration of Response, Pharmacokinetics, Immunogenicity
- Eligibility
- Adults with advanced urothelial carcinoma, specific treatment history requirements
- Exclusion Criteria
- Certain prior treatments, active infections, severe hypersensitivities, specific medical conditions
What are Antihistamines for Systemic Use?
Antihistamines for systemic use are a class of medications that work throughout the body to counteract the effects of histamine, a substance produced by the immune system during allergic reactions. These medications are designed to be taken orally and affect the entire body, as opposed to topical antihistamines that are applied to a specific area.
Medical Conditions Treated
While antihistamines are commonly used for allergic conditions, the clinical trial data provided focuses on their potential use in cancer treatment, specifically for advanced urothelial carcinoma. Urothelial carcinoma is a type of bladder cancer that affects the lining of the urinary system, including the bladder, renal pelvis, ureter, and urethra.
Current Clinical Trial
A Phase 1/2 clinical trial is currently being conducted to evaluate the safety and effectiveness of antihistamines for systemic use (referred to as MK-2870 in the trial) in combination with other cancer treatments for advanced urothelial carcinoma. The study, named KEYMAKER-U04, is investigating the following:
- The safety and tolerability of MK-2870 in combination with enfortumab vedotin (EV)
- The safety and tolerability of MK-2870 in combination with pembrolizumab and EV
- The overall response rate (ORR) of the combination treatments
The trial is divided into two parts: Part 1 focuses on patients who have previously received treatment for advanced urothelial carcinoma Part 2 involves patients who have not received prior systemic therapy for advanced urothelial carcinoma
Administration and Usage
In this clinical trial, antihistamines for systemic use (MK-2870) are administered orally. The exact dosing regimen and schedule will be determined as part of the study objectives.
Eligibility for the Clinical Trial
To participate in this clinical trial, patients must meet specific criteria. Some key eligibility factors include:
- Age 18 years or older
- Histologically documented advanced urothelial carcinoma
- Measurable disease according to RECIST 1.1 criteria
- ECOG performance status of 0 to 1 (indicating good overall health and ability to perform daily activities)
There are also several exclusion criteria, such as:
- Prior treatment with specific cancer therapies (e.g., FGFR inhibitors, Trop-2-targeted ADCs)
- Active autoimmune diseases
- Certain concurrent medical conditions
Safety Considerations
As with any clinical trial, safety is a primary concern. The study will closely monitor for adverse events (AEs) and discontinuations due to AEs. Patients with a history of severe hypersensitivity to the study drugs or their components are not eligible to participate.
It's important to note that while antihistamines are generally well-tolerated, their use in cancer treatment is still being investigated. Patients considering participation in this trial should discuss potential risks and benefits with their healthcare provider.